Abstract 129P
Background
Giant cell tumor of bone (GCTB) is an uncommon, benign, aggressive osteolytic skeletal malignancy affecting young adults. The purpose of this study was to examine the safety and efficacy of denosumab in patients with metastatic, unresectable, or resectable high-risk primary GCTB.
Methods
Patients with histologically proven GCTB over the age of 16 who received denosumab between January 2013 and September 2022 were analyzed retrospectively. Patients included in this study had metastatic, unresectable, or resectable high-risk primary tumors. Demographic characteristics of the patients, localization at the time of diagnosis, prior treatments, response to denosumab treatment, and adverse effects of the drug were documented.
Results
Of the 29 patients enrolled, 48.3 % (n = 14) were female. The median (IQR) age was 26,35 (16.13–45.03) years. Median follow-up time 71.93 ± 26.96 months. The primary lesions were located in lower limb (27.6%; n=8) in skull (20.7%; n=6), in vertebrae (24.1%; n=7), in upper limb (13.8%; n=4), and in pelvic bone (13.8%; n=4). Eighteen cases (62.1%) were assessed as resectable high-risk, 8 cases (27.6%) were unresectable, and three cases (10,3%) were metastatic. Seventeen patients (58.62%) with resectable high-risk disease had stable disease, and one (3.4%) had a partial response. Eight unresectable patients (27.58%) had stable disease. Two patients (6.8%) with metastatic disease had stable disease, and one (3.4%) with brain metastasis died.
Conclusions
In conclusion, denosumab treatment in GCTB is associated with a high rate of tumor control with a favorable profile in real-life as well as in clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hacettepe University, Ethics Boards and Commissions.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.